Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 119 Published: April 29, 2022 Report Code: GMDGDHC22075TDB

Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The Exportin 1 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Exportin 1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for XPO1 and features dormant and discontinued projects.

Key Therapy Areas in the Exportin 1 Pipeline Drugs Market

In the XPO1 pipeline drugs market the key therapy areas are Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders.

Exportin 1 Pipeline Drugs Market, by Therapy Areas

Exportin 1 Pipeline Drugs Market, by Therapy Areas

For more therapy areas insights, download a free report sample

Key MoA in the Exportin 1 Pipeline Drugs Market

The key MoA in the Exportin 1 pipeline drugs market is Exportin 1 Inhibitor.

Exportin 1 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Exportin 1 pipeline drugs market are oral, and topical.

Exportin 1 Pipeline Drugs Market Analysis, by RoA

Exportin 1 Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Exportin 1 Pipeline Drugs Market

The key molecule type in the Chromosomal Maintenance 1 pipeline drugs market is Small Molecule.

Major Companies in the Exportin 1 Pipeline Drugs Market

The major companies in the Exportin 1 pipeline drugs market are Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc.

Exportin 1 Pipeline Drugs Market, by Major Companies

Exportin 1 Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Exportin 1 Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders
Key Mechanisms of action Exportin 1 Inhibitor
Key Routes of Administration Oral, and Topical
Key Molecule Types Small Molecule
Major Companies Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Exportin 1
  • The pipeline guide reviews pipeline therapeutics for Exportin 1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Exportin 1 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Exportin 1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Exportin 1

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Exportin 1
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Exportin 1 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Biogen Inc

    CanBas Co Ltd

    Jiangsu Carephar Pharmaceutical Co Ltd

    Karyopharm Therapeutics Inc

    Oita University Institute of Advanced Medicine Inc

    Wigen Biomedicine Technology (Shanghai) Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Overview

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Companies Involved in Therapeutics Development

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Drug Profiles

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Dormant Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Discontinued Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Product Development Milestones

Featured News & Press Releases

Apr 06, 2022: Antengene’s pivotal “MARCH” study to evaluate selinexor (ATG-010) in relapsed or refractory multiple myeloma published in BMC Medicine

Mar 29, 2022: Antengene announces IND approval in China for a phase II study of Eltanexor (ATG-016) in patients with High-Risk Myelodysplastic Syndrome

Mar 16, 2022: Karyopharm announces upcoming presentations of phase 3 SIENDO study of selinexor in patients with advanced or recurrent endometrial cancer

Mar 09, 2022: Antengene announces XPOVIO approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma

Mar 01, 2022: Antengene announces XPOVIO regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications

Mar 01, 2022: Karyopharm provides U.S. regulatory update on Selinexor in advanced or recurrent Endometrial Cancer

Feb 08, 2022: Karyopharm announces Phase 3 SIENDO study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer

Jan 24, 2022: Karyopharm receives orphan drug designation from FDA for eltanexor for the treatment of myelodysplastic syndromes

Dec 29, 2021: Antengene announces first patient dosed in REACH study of ATG-016 for the treatment of advanced solid tumors

Dec 18, 2021: Antengene announces NDA approval by NMPA for XPOVIO, China’s first XPO1 inhibitor, for the treatment of adults with relapsed or refractory multiple myeloma

Dec 14, 2021: Antengene presents results of phase 1b TOUCH trial of Selinexor for the treatment of T and NK-Cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

Dec 11, 2021: Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition

Dec 06, 2021: Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician’s choice in previously treated myelofibrosis

Dec 02, 2021: Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer

Nov 18, 2021: Antengene announces IND approval in China for a phase I/II Study of Selinexor (ATG-010) in patients with non-Hodgkin lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Biogen Inc, 2022

Pipeline by CanBas Co Ltd, 2022

Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022

Pipeline by Karyopharm Therapeutics Inc, 2022

Pipeline by Oita University Institute of Advanced Medicine Inc, 2022

Pipeline by Wigen Biomedicine Technology (Shanghai) Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.